The Global Adalimumab Market was valued at USD 2.72 billion in 2024 and is anticipated to reach USD 3.56 billion by 2030, growing at a CAGR of 4.80% over the forecast period. Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-a), plays a pivotal role in managing autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. Its proven efficacy in controlling inflammation and slowing disease progression has made it a widely adopted therapy in immunology. The market's growth is primarily fueled by the rising incidence of chronic inflammatory diseases, greater awareness of biologic treatments, and increased healthcare investment, particularly in emerging economies. Despite ongoing pricing pressures in mature markets, global access to advanced therapies and increased diagnosis rates are expected to support sustained market expansion.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.72 Billion
Market Size 2030	USD 3.56 Billion
CAGR 2025-2030	4.80%
Fastest Growing Segment	Biologics
Largest Market	North America

Key Market Drivers

Growth in Healthcare Industry

The expanding global healthcare industry, generating annual revenues exceeding USD 4 trillion, is significantly driving the adalimumab market forward. Pharmaceuticals and biotechnology, accounting for nearly USD 850 billion, represent key contributors to this growth. As healthcare infrastructure improves across developed and emerging regions, diagnoses of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease are becoming more common-boosting demand for adalimumab. Advanced diagnostics and early intervention, made possible by rising investment in healthcare systems, are leading to increased use of targeted biologics. Government support, private sector investment, and broader insurance coverage are also making high-cost treatments more accessible. With global healthcare spending reaching USD 9.8 trillion in 2021, representing over 10% of global GDP, emerging markets are witnessing improved patient access to biologics through expanded hospital networks and reform-driven health systems. As a result, adalimumab continues to benefit from these advancements, cementing its position as a frontline treatment in immunology.

Key Market Challenges

High Cost of Production

A key challenge in the global adalimumab market is the high cost of biologic drug production. The manufacturing of adalimumab, a complex monoclonal antibody, involves intricate biotechnological methods that require substantial investment in specialized infrastructure, skilled personnel, and regulatory compliance. The use of living cells in the development process, combined with tightly controlled manufacturing conditions, contributes to elevated production costs. Critical stages such as cell culture, purification, and formulation are both time-consuming and resource-intensive. Furthermore, risks such as batch failure and the rigorous validation requirements further strain cost efficiency. These high production costs pose a barrier for manufacturers, particularly when attempting to scale or introduce biosimilars in competitive markets.

Key Market Trends

Rising Prevalence of Chronic Diseases

The growing incidence of autoimmune and inflammatory diseases represents a significant trend shaping the adalimumab market. Conditions like rheumatoid arthritis, ulcerative colitis, psoriasis, and Crohn's disease are becoming more prevalent, driven by aging populations, sedentary lifestyles, and environmental triggers. As these chronic conditions often require long-term treatment, demand for reliable and effective biologics continues to rise. Adalimumab, with its broad therapeutic indications and established clinical profile, remains a preferred option for managing chronic inflammation. It was the first fully human monoclonal antibody to receive approval for rheumatoid arthritis and has since proven its safety and efficacy in long-term use. This growing reliance on biologics underscores the sustained role of adalimumab in immunological treatment strategies worldwide.

Key Market Players

AbbVie Inc.
Pfizer, Inc.
Amgen Inc.
Novartis AG
Torrent Pharmaceuticals Ltd.
Cadila Healthcare Limited
Boehringer Ingelheim International GmbH
Mylan N.V.
Hetero Biopharma Ltd
Samsung Bioepis Co Ltd.

Report Scope

In this report, the Global Adalimumab Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Adalimumab Market, By Type:

Biologics
Biosimilars

Adalimumab Market, By Therapeutic Area:

Rheumatoid Arthritis
Psoriatic Arthritis
Psoriasis
Crohn's Disease
Others

Adalimumab Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adalimumab Market.

Available Customizations

Global Adalimumab Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Adalimumab Market

5. Global Adalimumab Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Biologics, Biosimilars)
- 5.2.2. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Adalimumab Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Therapeutic Area
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Adalimumab Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Therapeutic Area
- 6.3.2. Mexico Adalimumab Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Therapeutic Area
- 6.3.3. Canada Adalimumab Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Therapeutic Area

7. Europe Adalimumab Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Therapeutic Area
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Adalimumab Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Therapeutic Area
- 7.3.2. Germany Adalimumab Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Therapeutic Area
- 7.3.3. United Kingdom Adalimumab Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Therapeutic Area
- 7.3.4. Italy Adalimumab Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Therapeutic Area
- 7.3.5. Spain Adalimumab Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Adalimumab Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Therapeutic Area
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Adalimumab Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Therapeutic Area
- 8.3.2. India Adalimumab Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Therapeutic Area
- 8.3.3. South Korea Adalimumab Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Therapeutic Area
- 8.3.4. Japan Adalimumab Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Therapeutic Area
- 8.3.5. Australia Adalimumab Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Therapeutic Area

9. South America Adalimumab Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Therapeutic Area
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Adalimumab Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Therapeutic Area
- 9.3.2. Argentina Adalimumab Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Therapeutic Area
- 9.3.3. Colombia Adalimumab Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Therapeutic Area

10. Middle East and Africa Adalimumab Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Therapeutic Area
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Adalimumab Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Therapeutic Area
- 10.3.2. Saudi Arabia Adalimumab Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Therapeutic Area
- 10.3.3. UAE Adalimumab Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Adalimumab Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. AbbVie Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Pfizer, Inc.
16.3. Amgen Inc.
16.4. Novartis AG
16.5. Torrent Pharmaceuticals Ltd.
16.6. Cadila Healthcare Limited
16.7. Boehringer Ingelheim International GmbH
16.8. Mylan N.V.
16.9. Hetero Biopharma Ltd
16.10. Samsung Bioepis Co Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION